AVE 33.3% 0.2¢ avecho biotechnology limited

it`s the balance sheet stupid, page-8

  1. 5,322 Posts.
    And I agree with you entirely gmutton re PR. POH needs to keep spruiking Its new Body shaper Creme and Elixia High Performance offering and keep us apprised of sales success. I do not however agree the market sees any monkeys on POHs back as you put it. The shares were overbought yesterday and oversold today. My view going forward is that the co can indeed become become cash positive in 2012 (our CEO has stated this in media this week)......but the funding of late stage trials for OXy patch will need to come from a partner via milestones (could be done on back of 3M patch scale up completion) or via a placement specifically for a phase2/3 trial. We will know soon enough as the 3M work must be close to done and the trials are to commence 2nd half this year...a little patience will be well rewarded
 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.